Trial
NCT02621515
Nivo/Ipi Combination Therapy in Symptomatic Brain Metastases
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
University Medical Center Groningen
Collaborators
—
Condition
Melanoma
Intervention
Nivolumab
Why stopped
In the Netherlands we wanted to add pilimumab to nivolumab. This resulted in a very long METC procedure which resulted in a to slow inclusion rate.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-05-06